Navigation Links
Genoptix Reports Strong Financial Results for the Third Quarter and Raises Guidance for Full-Year 2008
Date:11/6/2008

project capital expenditures of approximately $11.0 million for the full-year 2008.

For 2009, the Company expects revenues of approximately $165 million and a tax rate of approximately 45%.

Conference Call Information

A conference call will take place on Thursday, November 6, 2008, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time), hosted by President and CEO, Tina S. Nova, Ph.D., and other members of senior management. To access the live conference call via phone, dial 800-561-2693 in the U.S. or Canada and 617-614-3523 for international callers. Please specify to the operator that you would like to join the "Genoptix Third Quarter 2008 Earnings Conference Call." The participant code for the call is 61140638. If you are unable to listen to the live webcast, a replay of the call will be available through Thursday, November 13, 2008. Interested parties can access the rebroadcast by dialing 1-888-286-8010 or 1-617-801-6888 internationally and entering the reservation number 60056810.

The conference call will also be webcast live under the investor relations section of the Genoptix website at http://www.genoptix.com. Please connect to the Genoptix website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary. If you are unable to listen to the live webcast, a replay will be available through Friday, December 5, 2008, on the Genoptix website at http://www.genoptix.com.

About Genoptix, Inc.

Genoptix is a specialized laboratory service provider focused on delivering personalized and comprehensive diagnostic services to community-based hematologists and oncologists. Genoptix is headquartered in Carlsbad, California.

Non-GAAP Financial Measures

In addition to disclosing financial results calculated in accordance with generally accepted accounting pr
'/>"/>

SOURCE Genoptix, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Genoptix, Inc. Announces Pricing for Initial Public Offering
2. Genoptix, Inc. to Announce Fourth Quarter and Full Year 2007 Financial Results on February 12, 2008
3. Genoptix Reports Strong Financial Results for the Fourth Quarter and Full Year 2007
4. Genoptix Announces Filing of Registration Statement for Secondary Public Offering of Common Stock
5. Genoptix Announces Pricing of Secondary Public Offering
6. Genoptix Announces Participation at Cowen and Company 28th Annual Health Care Conference
7. Genoptix Announces Participation at Lehman Brothers 11th Annual Global Health Care Conference
8. Genoptix Announces 2008 Annual Stockholders Meeting and Date of Record
9. Genoptix Announces Participation at the Bank of America 2008 Healthcare Conference
10. Genoptix Reports Strong Financial Results for First Quarter 2008
11. Genoptix Reports Strong Financial Results for the Second Quarter and Raises Guidance for Full-Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)..., , NEW YORK, Dec. 4 Tho... than 90 offices nationwide today, to participate ...dit, tax and advisory firm,s support for literacy ...ice day reflects our firm,s long history of volunt...gathered in the spirit of caring to brighten the h...
(Date:12/4/2009)..., , SCOTTSDALE, Ariz., Dec. 4 /PRNewswire/...elf-managed, non-traded, real estate investment tr...e agreement to acquire a three building medical of...cana, Texas, and Fort Wayne, Indiana for approxima...is subject to the satisfaction of a number of cond...
(Date:12/4/2009)..., , WASHINGTON, Dec. 4 /PRNewswire-USNew...re reform would control health care costs, Leapfro...ead through example -- delivering the best quality...vels of efficiency. Thirty-four urban, eight child...09 Leapfrog Top Hospitals, based on results from T...
(Date:12/4/2009)..., Working with mice, scientists at Johns Hopkins...ave shown that a protein made by a gene called "Tw...ately distinguish stem cells that drive aggressive...r cells. , Building on recent work suggesting th...in breast tumors that drives breast cancer, scient...
(Date:12/4/2009)... Dental tourism is a phen...g for an alternative to the high price of dental w...ir search for lower priced dental care, people hav...oice as a dental tourist destination. , ...eing in business for more than 6 years, Mexican De...
Breaking Medicine News(10 mins):Health News:KPMG Employees Provide 'Holiday Bear Hugs' and Books in Firmwide Service Day for Children 2Health News:Healthcare Trust of America, Inc. Executes Agreement to Acquire a 92,500 Square Foot Medical Office Portfolio Located in Texas and Indiana 2Health News:The Leapfrog Group Releases Its 2009 Top Hospitals List 2Health News:The Leapfrog Group Releases Its 2009 Top Hospitals List 3Health News:Potential new 'twist' in breast cancer detection 2Health News:Potential new 'twist' in breast cancer detection 3Health News:Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor 2Health News:Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor 3
... 2008 Elderly patients who use antipsychotic drug...neumonia compared to non-users. This risk is highe...creases gradually thereafter. These findings are p...and behavioral problems associated with dementia a...
... Weems, Congressman Gene Green,Among High-Level Pa... in,Health Care At U.S. News & World Report Breakf...,issued by U.S. News & World Report:, EVENT TOPIC...are, will examine the "value paradigm",between adv...
...s more than 786,000 workers, CHICAGO, April 15 T...e release of its updated statistical map entitled ...sion in 2006" that details how,many employees, bro...se employees. The data clearly shows how much the,...
...ve Workflow Tools Will Help Public Health Move Be...True Community Health Surveillance ...g Systems (HMS), (http://www.hmsinc.com ), pioneer...ools that empower epidemiologists and others in,pu...
...sults of a phase IV, open label, head-to-head stud...uency subcutaneous Rebif (interferon beta-1a) prov...lar efficacy over 18 to 30 months of continued the... and Opinion journal. , The Prospective and Retro...
...ses too much on treatments and not enough on preve...run for many women, say researchers at Michigan St...ias coverage of the disease found that over a two-...t, while only 18 percent looked at prevention. , ...
Other Medicine News:Health News:Top Policy Experts to Debate Link Between Rising Health Care Costs and Advances in Medical Technology, Wednesday, April 16, 2008, From 8:30 - 10:00 A.M., at DC's National Press Club 2Health News:Academy of General Dentistry Releases Updated Employment Statistical Map 2Health News:Health Monitoring Systems Releases EpiCenter(TM) 2Health News:Health Monitoring Systems Releases EpiCenter(TM) 3Health News:Health Monitoring Systems Releases EpiCenter(TM) 4Health News:Study shows that high-dose, high-frequency interferon produces no additional benefit 2Health News:Study finds media coverage of breast cancer focuses too little on prevention 2
(Date:12/4/2009)...NGTON, Dec. 4 Chemistr...shed by the Pharmaceutical Research and Manufactu...drugs and vaccines in development for HIV/AIDS and...hat the 97 products in development include 23 vacc...human clinical trials or awaiting approval by the ...
(Date:12/4/2009).... 4 PharmAthene, Inc. (N...medical countermeasures against biological and che... presenting results of a study demonstrating the e...thrax model in the New Zealand White (NZW) rabbit....ion at the HHS Public Health Emergency Medical Cou...
(Date:12/4/2009)...STON, Dec. 4 OrthoAccel Technologi...hich is an acceleration device to enhance orthodon...ng Education course published by PennWell Corpora... industries, including medicine and dentistry. Th...c treatment, a summary of treatment biomechanics, ...
Breaking Medicine Technology:U.S. Pharmaceutical Companies Developing 97 New Drugs and Vaccines to Fight HIV/AIDS 2PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 2PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 3PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 4PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 5PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 6AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 2AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 3AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 4State National Nursing Home Caregivers 3A Medicare Funding Cut to Long Term Care Will Jeopardize Vital Staffing Positions and Compromise Care for New 54470 1State National Nursing Home Caregivers 3A Medicare Funding Cut to Long Term Care Will Jeopardize Vital Staffing Positions and Compromise Care for New 54470 2State National Nursing Home Caregivers 3A Medicare Funding Cut to Long Term Care Will Jeopardize Vital Staffing Positions and Compromise Care for New 54470 3Korea Institute of Toxicology Implementing Xybion 26apos 3Bs Pristima 26amp 3B 238482 3B 13553 1Korea Institute of Toxicology Implementing Xybion 26apos 3Bs Pristima 26amp 3B 238482 3B 13553 2Patheon Announces Date of Third Quarter 2009 Financial Results Release Conference Call and Webcast 54467 1Patheon Announces Date of Third Quarter 2009 Financial Results Release Conference Call and Webcast 54467 2
...E: LLY ) has submitted a supplemental New Drug Ap...tration (FDA) seeking approval for a new,indicatio...ent of chronic,pain, the company announced today. ...ials in chronic osteoarthritis pain of the knee an...previously completed pain studies in,diabetic peri...
...ccessfully placed in three patient...May 29 Three patients with established,cardiac is... vProtect,Luminal Shield, a self-expanding intraco...y that typically occurs when stents are deployed. ...ort for the vessel to ensure that,the target coron...
Other Medicine Technology:Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration 2Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration 3Prescient Medical, Inc. Achieves Successful Clinical Debut of vProtect(TM) Luminal Shield 2
Avitene Flour
CODMAN Steerable Neuroendoscope
D185 MultiPulse Cortical Stimulator
The Wilson Plus Radiolucent Wilson Frame
Medicine Products: